Lead Product(s) : Allogenic Pancreatic Islet Cell
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Kadimastem
Deal Size : Inapplicable
Deal Type : Inapplicable
Kadimastem, iTolerance Complete Pre-IND Meeting for Type 1 Diabetes Therapy
Details : iTOL-102 is developed using proprietary SA-FasL biotin-PEG microgel platform, which being developed as a potential cure for Type 1 Diabetes without the need for chronic immunosuppression.
Product Name : iTOL-102
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : Allogenic Pancreatic Islet Cell
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Kadimastem
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain
Details : The partnership aims to enhance the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity, leveraging Ginkgo's synthetic biology platform for new methods.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
5 Prime Sciences Announces Strategic Collaboration with Lilly in Cardio-Metabolic Diseases
Details : Under the collaboration, 5 Prime Sciences will utilize its advanced human genetics and AI technologies to identify and validate potential drug targets for cardio-metabolic diseases & diabetes.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : IGC-1A
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IGC Pharma Expands Portfolio with GLP-1 Agonist for Metabolic Disorders
Details : IGC-1A is a potential new GLP-1 agonist. Currently, it is being evaluated in the discovery stage for the treatment of patients suffering from diabetes.
Product Name : IGC-1A
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2024
Lead Product(s) : IGC-1A
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration
Details : Collaboration leverages Sentia’s platform and Neurocrine’s expertise to develop novel CRF receptor antagonists.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Michigan Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to explore mechanisms of metabolic improvement and weight loss from an intrapancreatic gene therapy leveraging GLP-1-based transgenes for long-duration treatment of type 2 diabetes (T2D) and obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Michigan Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Vertex Pharmaceuticals
Deal Size : $1,200.0 million
Deal Type : Expanded Collaboration
Details : Under the terms of the agreement, Vertex Pharmaceuticals incorporated will receive rights to Arbor’s novel precision editing technology for up to three diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Vertex Pharmaceuticals
Deal Size : $1,200.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : JDRF
Deal Size : Undisclosed
Deal Type : Partnership
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
Details : The partnership aims to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb,a murine surrogate of teplizumab, to tolerize, deplete or modulate diabetes antigen-specific T cells.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 24, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : JDRF
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Century Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 11, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Century Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the research collaboration, Sentia’s proprietary peptide-based platform will be used to discover novel compounds as corticotropin-releasing factor receptor antagonist for the treatment of hypothalamic-pituitary-adrenal axis modulated diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration